Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma

An association with type I anti-neuronal nuclear antibodies

Edward Dropcho, Peter H. King

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Hel-N1 is a novel human complementary DNA encoding a neuronal RNA-binding protein which shares considerable sequence homology with the HuD protein, a target of type 1 anti-neuronal nuclear antibodies in patients with paraneoplastic encephalomyelitis. The aim of the present study was to determine the prevalence of antibodies against the Hel-N1 protein among patients with lung carcinoma, including those with paraneoplastic disorders. Sera from 45 patients with lung cancer (42 with small-cell carcinoma) and from 28 control patients with other neurological diseases were studied by enzyme-linked immunosorbent assay (ELISA) and by immunoblotting with recombinant Hel-N1 protein. Sixteen of the 45 lung cancer patients (14 with small-cell and 2 with undifferentiated carcinoma) had paraneoplastic encephalomyelitis and high-titer type I anti-neuronal nuclear antibodies; sera from each of these 16 patients also showed strong reactivity with Hel- N1 protein. The other 29 lung cancer patients, all of whom had neurological dysfunction and 24 of whom had known or suspected paraneoplastic disorders, lacked the type I antibody by standard testing. The mean anti-Hel-N1 titer (by ELISA) of sera from patients negative for type I anti-neuronal nuclear antibody was significantly less than that of the patients positive for the type I antibody, but exceeded that of the control patients with other neurological diseases (p <0.001). Fifteen (52%) of the 29 type I antibody- negative patients had positive serum anti-Hel-N1 titers which did not overlap the high anti-Hel-N1 titers of the 16 type I antibody-positive patients. These findings support the theory that type I anti-neuronal nuclear antibodies react with a family of neuronal RNA-binding proteins, and suggest that these proteins share one or more epitopes. High titers of circulating anti-Hel-N1 antibodies correlate with paraneoplastic encephalomyelitis, while lower anti-Hel-N1 titers are present in a sizeable proportion of patients with small-cell lung cancer without a clear association with their clinical condition.

Original languageEnglish (US)
Pages (from-to)200-205
Number of pages6
JournalAnnals of Neurology
Volume36
Issue number2
DOIs
StatePublished - Aug 1994
Externally publishedYes

Fingerprint

RNA-Binding Proteins
Autoantibodies
Carcinoma
Lung
Antibodies
Nervous System Paraneoplastic Syndromes
Lung Neoplasms
Serum
Proteins
Enzyme-Linked Immunosorbent Assay
Small Cell Carcinoma
Small Cell Lung Carcinoma
Sequence Homology
Immunoblotting
Epitopes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

@article{006b1e57637a448dbbad1a6634dc4a97,
title = "Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma: An association with type I anti-neuronal nuclear antibodies",
abstract = "Hel-N1 is a novel human complementary DNA encoding a neuronal RNA-binding protein which shares considerable sequence homology with the HuD protein, a target of type 1 anti-neuronal nuclear antibodies in patients with paraneoplastic encephalomyelitis. The aim of the present study was to determine the prevalence of antibodies against the Hel-N1 protein among patients with lung carcinoma, including those with paraneoplastic disorders. Sera from 45 patients with lung cancer (42 with small-cell carcinoma) and from 28 control patients with other neurological diseases were studied by enzyme-linked immunosorbent assay (ELISA) and by immunoblotting with recombinant Hel-N1 protein. Sixteen of the 45 lung cancer patients (14 with small-cell and 2 with undifferentiated carcinoma) had paraneoplastic encephalomyelitis and high-titer type I anti-neuronal nuclear antibodies; sera from each of these 16 patients also showed strong reactivity with Hel- N1 protein. The other 29 lung cancer patients, all of whom had neurological dysfunction and 24 of whom had known or suspected paraneoplastic disorders, lacked the type I antibody by standard testing. The mean anti-Hel-N1 titer (by ELISA) of sera from patients negative for type I anti-neuronal nuclear antibody was significantly less than that of the patients positive for the type I antibody, but exceeded that of the control patients with other neurological diseases (p <0.001). Fifteen (52{\%}) of the 29 type I antibody- negative patients had positive serum anti-Hel-N1 titers which did not overlap the high anti-Hel-N1 titers of the 16 type I antibody-positive patients. These findings support the theory that type I anti-neuronal nuclear antibodies react with a family of neuronal RNA-binding proteins, and suggest that these proteins share one or more epitopes. High titers of circulating anti-Hel-N1 antibodies correlate with paraneoplastic encephalomyelitis, while lower anti-Hel-N1 titers are present in a sizeable proportion of patients with small-cell lung cancer without a clear association with their clinical condition.",
author = "Edward Dropcho and King, {Peter H.}",
year = "1994",
month = "8",
doi = "10.1002/ana.410360212",
language = "English (US)",
volume = "36",
pages = "200--205",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma

T2 - An association with type I anti-neuronal nuclear antibodies

AU - Dropcho, Edward

AU - King, Peter H.

PY - 1994/8

Y1 - 1994/8

N2 - Hel-N1 is a novel human complementary DNA encoding a neuronal RNA-binding protein which shares considerable sequence homology with the HuD protein, a target of type 1 anti-neuronal nuclear antibodies in patients with paraneoplastic encephalomyelitis. The aim of the present study was to determine the prevalence of antibodies against the Hel-N1 protein among patients with lung carcinoma, including those with paraneoplastic disorders. Sera from 45 patients with lung cancer (42 with small-cell carcinoma) and from 28 control patients with other neurological diseases were studied by enzyme-linked immunosorbent assay (ELISA) and by immunoblotting with recombinant Hel-N1 protein. Sixteen of the 45 lung cancer patients (14 with small-cell and 2 with undifferentiated carcinoma) had paraneoplastic encephalomyelitis and high-titer type I anti-neuronal nuclear antibodies; sera from each of these 16 patients also showed strong reactivity with Hel- N1 protein. The other 29 lung cancer patients, all of whom had neurological dysfunction and 24 of whom had known or suspected paraneoplastic disorders, lacked the type I antibody by standard testing. The mean anti-Hel-N1 titer (by ELISA) of sera from patients negative for type I anti-neuronal nuclear antibody was significantly less than that of the patients positive for the type I antibody, but exceeded that of the control patients with other neurological diseases (p <0.001). Fifteen (52%) of the 29 type I antibody- negative patients had positive serum anti-Hel-N1 titers which did not overlap the high anti-Hel-N1 titers of the 16 type I antibody-positive patients. These findings support the theory that type I anti-neuronal nuclear antibodies react with a family of neuronal RNA-binding proteins, and suggest that these proteins share one or more epitopes. High titers of circulating anti-Hel-N1 antibodies correlate with paraneoplastic encephalomyelitis, while lower anti-Hel-N1 titers are present in a sizeable proportion of patients with small-cell lung cancer without a clear association with their clinical condition.

AB - Hel-N1 is a novel human complementary DNA encoding a neuronal RNA-binding protein which shares considerable sequence homology with the HuD protein, a target of type 1 anti-neuronal nuclear antibodies in patients with paraneoplastic encephalomyelitis. The aim of the present study was to determine the prevalence of antibodies against the Hel-N1 protein among patients with lung carcinoma, including those with paraneoplastic disorders. Sera from 45 patients with lung cancer (42 with small-cell carcinoma) and from 28 control patients with other neurological diseases were studied by enzyme-linked immunosorbent assay (ELISA) and by immunoblotting with recombinant Hel-N1 protein. Sixteen of the 45 lung cancer patients (14 with small-cell and 2 with undifferentiated carcinoma) had paraneoplastic encephalomyelitis and high-titer type I anti-neuronal nuclear antibodies; sera from each of these 16 patients also showed strong reactivity with Hel- N1 protein. The other 29 lung cancer patients, all of whom had neurological dysfunction and 24 of whom had known or suspected paraneoplastic disorders, lacked the type I antibody by standard testing. The mean anti-Hel-N1 titer (by ELISA) of sera from patients negative for type I anti-neuronal nuclear antibody was significantly less than that of the patients positive for the type I antibody, but exceeded that of the control patients with other neurological diseases (p <0.001). Fifteen (52%) of the 29 type I antibody- negative patients had positive serum anti-Hel-N1 titers which did not overlap the high anti-Hel-N1 titers of the 16 type I antibody-positive patients. These findings support the theory that type I anti-neuronal nuclear antibodies react with a family of neuronal RNA-binding proteins, and suggest that these proteins share one or more epitopes. High titers of circulating anti-Hel-N1 antibodies correlate with paraneoplastic encephalomyelitis, while lower anti-Hel-N1 titers are present in a sizeable proportion of patients with small-cell lung cancer without a clear association with their clinical condition.

UR - http://www.scopus.com/inward/record.url?scp=0028025677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028025677&partnerID=8YFLogxK

U2 - 10.1002/ana.410360212

DO - 10.1002/ana.410360212

M3 - Article

VL - 36

SP - 200

EP - 205

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -